4DX and SCREENX Drive 32% Box Office Growth Versus Overall Market’s Forecasted 9.1% Increase

Performance Fueled by Blockbuster Titles Including Avatar: Fire and Ash, Jurassic World Rebirth and How to Train Your Dragon

BURBANK, Calif., Feb. 16, 2026 /PRNewswire/ — CJ 4DPLEX, the world’s leading producer of premium film formats and cinema technologies, today announced exceptional 2025 performance across its premium formats. 4DX and SCREENX together generated $497 million in global box office, delivering 32% year-over-year growth and significantly outperforming the broader theatrical market.

The company’s continued expansion was driven by strong exhibitor demand, premium format adoption, and a robust slate of blockbuster releases that resonated with audiences seeking immersive theatrical experiences. In 2025, CJ 4DPLEX signed 198 new locations with leading exhibitors including AMC, Cinepolis, Cinemark, and Showtime Cinemas. Combined global screen count for 4DX and SCREENX reached 1,245 locations worldwide.

“2025 was a defining year for CJ 4DPLEX as both 4DX and SCREENX delivered extraordinary growth in revenue and global footprint,” said Jun Bang, CEO of CJ 4DPLEX. “Continued expansion across worldwide locations, combined with the sustained outperformance of our formats, demonstrates the strength of premium cinema experiences and the increasing value they bring to our exhibitor partners and the industry as a whole.”

4DX Delivers Record Growth in the U.S. and Globally

4DX delivered standout performance in 2025, generating $81 million in U.S. box office across just 67 screens and $289 million internationally, for a total of $370 million globally, representing 31% year-over-year growth.

The format’s motion seating, environmental effects, and immersive design continued to attract younger moviegoers and event-driven audiences, reinforcing 4DX’s position as a powerful driver of incremental attendance, premium pricing, and higher per-screen averages for exhibitors.

SCREENX Continues Strong Momentum Worldwide

SCREENX also delivered strong growth in 2025, generating $35 million in U.S. box office and $92 million globally, representing a 37% year-over-year increase.

The panoramic, multi-screen format has become an increasingly important premium offering for exhibitors seeking differentiated content experiences, enhanced per-screen performance, and greater flexibility in programming major studio releases.

Strategic Investment in Technology and Content Strengthens Long-Term Growth

In 2025, CJ 4DPLEX materially strengthened its technology and content foundation, positioning SCREENX for accelerated global scale. A key initiative was expanded investment in the company’s Seoul-based VFX business, enabling a significant increase in the number of SCREENX titles produced annually, as well as a meaningful expansion in the number of minutes per film utilizing the full 270-degree format.

At the same time, CJ 4DPLEX completed a comprehensive redesign of the SCREENX technology platform, enhancing image quality, synchronization, calibration, and operational reliability. This next-generation SCREENX system has now been successfully implemented with key strategic partners, including a full deployment across Cinemark’s SCREENX locations and all newly built AMC SCREENX auditoriums, highlighted by AMC’s flagship and highest-performing location in Burbank.

“2025 validated our strategy to invest simultaneously in premium format scale, content capability, and technology,” said Don Savant, CEO of CJ 4DPLEX Americas. “Audiences are clearly choosing premium experiences, and our investments in SCREENX VFX, expanded 270-degree storytelling, and next-generation technology are translating into stronger per-screen performance and repeatable economics for exhibitors. As we enter 2026 with a robust studio slate and growing backlog, we are well positioned to continue outperforming the broader market.”

The result is a structurally stronger technology foundation that materially improves CJ 4DPLEX’s competitive position, enhances exhibitor confidence, and supports long-term profitability as the SCREENX network continues to scale globally.

About CJ 4DPLEX
CJ 4DPLEX is a proud subsidiary of CJ Group, Korea’s leading lifestyle and culture company. Headquartered in Sangam, Seoul, we design and develop immersive cinema technologies that inspire audiences worldwide. Guided by creativity, technology, and cultural vision, we are committed to redefining the future of cinema starting right here in Korea.

CJ 4DPLEX is redefining the moviegoing experience across many countries worldwide, working with the world’s top exhibitors to deliver SCREENX, 4DX and ULTRA 4DX to audiences everywhere. From the United States to Europe, Asia, and the Middle East, our global presence keeps growing driven by our mission to make immersive storytelling the standard in cinema. Innovation drives us to connect people beyond language and borders through shared experiences.

About SCREENX
SCREENX is the world’s most immersive platform, breaking free from the boundaries of a single screen to place audiences at the heart of the story.

With visuals flowing seamlessly across the walls, SCREENX connects film and space, creating moments of true natural immersion. Every sequence is curated to reflect the director’s vision, turning each film into a journey only SCREENX can deliver.

About 4DX
4DX provides the best synesthetic viewing experience that connects the audience with movies through its state-of-the-art motion-seats and 21 environmental effects that include water, wind and scents. The 4DX theater is a special theater where you can feel various environmental effects such as wind, light, fog, fragrance, and vibration, as well as motion chairs that move according to the scene of the movie. Audiences can feel a new level of 4DX effect that maximizes vividness in each scene beyond simply watching movies with limitations of existing video and sound.

CJ 4DPLEX can be found at www.cj4dplex.com.

TULSA, Okla., Feb. 16, 2026 /PRNewswire/ — Zeeco, a global leader in advanced combustion and environmental solutions, today announced the acquisition of Applicot Corporation, a leading Japanese combustion company. This strategic move strengthens Zeeco’s footprint in the Japanese domestic market and enhances local support for Engineering, Procurement, and Construction (EPC) customers throughout the region.

Darton Zink (left) and Susumu Morita shake hands after they finalize the acquisition of Applicot by Zeeco, Inc.

Applicot has operated as an official licensee of Zeeco for more than 35 years. Zeeco’s acquisition of the company combines Applicot’s strong market presence with Zeeco’s global resources, manufacturing infrastructure, and innovative technologies to deliver comprehensive combustion solutions to customers in Japan.

“Bringing Applicot fully into the Zeeco family marks an exciting milestone in our growth strategy,” said Darton Zink, President and CEO of Zeeco. “This acquisition reinforces our commitment to providing localized expertise backed by global capabilities, ensuring our customers receive the highest level of service and support.”

While Applicot’s core business has historically focused on flare systems, Zeeco plans to expand Applicot’s capabilities to include a full range of combustion and environmental solutions, delivering greater value to customers across multiple industries.

“Zeeco has played a trusted and important role in Applicot’s history for decades,” said Susumu Morita, Managing Director of Applicot. “Becoming a fully integrated member of the Zeeco family is a natural progression and one that creates new opportunities for our team and the customers we proudly serve.”

Applicot will remain a trusted brand in Japan as a wholly owned subsidiary of Zeeco. Zeeco’s acquisition of Applicot was finalized on January 13, 2026.

About Zeeco, Inc. 
Founded in 1979, Zeeco has steadily become the world leader in designing and manufacturing advanced combustion and environmental solutions. Headquartered in Tulsa, Oklahoma, USA, Zeeco is a privately held business with more than 3,000 employees and 30+ global locations. The company executes thousands of projects yearly for refining, production, petrochemical, LNG, power, pharmaceutical, biogas, and other industries. ZEECO® products and solutions include ultra-low-NO_x burners, flare systems, thermal oxidizers, vapor control, rentals, aftermarket solutions, global field services, combustion electronics, and process heaters. Zeeco’s comprehensive offering helps customers reduce emissions, optimize processes, and maximize operating efficiency while meeting global environmental compliance requirements. Zeeco also operates the world’s largest combustion research and testing facility, as well as a manufacturing facility, on a 250-acre campus at its Global Technology Center in Broken Arrow, Oklahoma, USA. Learn more at Zeeco.com. 

About Applicot Corporation
Applicot Corporation, a wholly owned subsidiary of Zeeco based in Yokohama, Japan, was founded in 1986 and has maintained a strong relationship with Zeeco for nearly 40 years. For decades, Applicot has supplied combustion equipment for capital projects throughout Japan and beyond. As part of Zeeco, Applicot continues to support customers in Japan and abroad with reliable products and local expertise.

Contact: Mandy Vavrinak
Crossroads Communications
(918) 633-4397
mandy@crossroads-team.com 

Photo – https://laotiantimes.com/wp-content/uploads/2026/02/zeeco_darton_zink_susumu_morita__applicot_closing.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2026/02/zeeco_logo_logo.jpg

HIGHLIGHTS

• Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released.
• The study was led by Prof Louise Emmett at St Vincent’s Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026.
• Co-PSMA IIT evaluated the performance of Clarity’s diagnostic product, ⁶⁴Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) ⁶⁸Ga-PSMA-11 in 50 patients with biochemical recurrence (BCR) of prostate cancer (with prostate-specific antigen [PSA] 0.2-0.75 ng/mL) following radical prostatectomy who were candidates for curative salvage therapy.
• ⁶⁴Cu-SAR-bisPSMA positron emission tomography (PET) / computed tomography (CT) identified a statistically significant greater number of prostate cancer lesions per patient than ⁶⁸Ga-PSMA-11 PET/CT (study primary endpoint). The mean per-patient lesion was 1.26 for ⁶⁴Cu-SAR-bisPSMA vs. 0.48 for ⁶⁸Ga-PSMA-11, with a difference of 0.78 (95% confidence interval [CI]: 0.52 – 1.04), ratio 2.63 (95%CI: 1.64 – 4.20) (p <0.0001).
• In total, ⁶⁸Ga-PSMA-11 identified 24 lesions across all participants, while ⁶⁴Cu-SAR-bisPSMA next-day imaging detected 63 lesions.
• At a per-patient level, ⁶⁸Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while ⁶⁴Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.
• Planned patient management changed following assessment of ⁶⁴Cu-SAR-bisPSMA PET/CT in 22/50 (44%) trial participants.
• Further data outlining results from the Co-PSMA IIT will be presented at the EAU Congress 2026.

SYDNEY, Feb. 16, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the release of an abstract on the Co-PSMA (NCT06907641)^[1] IIT, accepted for oral presentation at the upcoming EAU Congress 2026, Europe’s largest urological conference, to be held from 13 to 16 March 2026 in London, UK^[2]. The abstract outlines key findings from the study.

Co-PSMA (“Comparative performance of ⁶⁴Copper [⁶⁴Cu]-SAR-bisPSMA vs. ⁶⁸Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy”) was led by Prof Louise Emmett at St Vincent’s Hospital Sydney. This Phase II IIT evaluated the performance of Clarity’s diagnostic product, ⁶⁴Cu-SAR-bisPSMA, in a head-to-head comparison to SOC ⁶⁸Ga-PSMA-11 in 50 prostate cancer patients with BCR who were candidates for curative salvage therapy. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA level between 0.2 and 0.75 ng/mL. ⁶⁸Ga-PSMA-11 PET/CT was followed by ⁶⁴Cu-SAR-bisPSMA PET/CT within 3 weeks (at 1 h and 24 h post-injection, same-day and next-day imaging, respectively), on the same digital PET camera. A standard of truth (SOT) was used to determine accuracy of the PET findings and included biopsy, response to targeted treatment without androgen deprivation therapy [ADT] or corroborative imaging. The primary endpoint of the Co-PSMA study was to assess the difference in mean per patient lesion number.

⁶⁴Cu-SAR-bisPSMA PET/CT identified a statistically significant greater number of lesions per participant than ⁶⁸Ga-PSMA-11 PET/CT, with a higher true positive rate also favouring ⁶⁴Cu-SAR-bisPSMA. The mean per-patient lesion for ⁶⁴Cu-SAR-bisPSMA was 1.26, compared to 0.48 for ⁶⁸Ga-PSMA-11, with a difference of 0.78 (95%CI: 0.52 – 1.04), ratio 2.63 (95%CI: 1.64 – 4.20) (p <0.0001). In total, ⁶⁸Ga-PSMA-11 identified 24 lesions across all participants, while ⁶⁴Cu-SAR-bisPSMA next-day imaging detected 63 lesions. On a per patient level, 36% (18/50) of participants were positive on ⁶⁸Ga-PSMA-11 PET/CT, compared to 78% (39/50) on the ⁶⁴Cu-SAR-bisPSMA PET/CT (next-day imaging). Planned patient management changed following the assessment of the ⁶⁴Cu-SAR-bisPSMA scans in 22/50 (44%) trial participants. Among the participants with an evaluable SOT, the true positive rate was 75% for ⁶⁴Cu-SAR-bisPSMA (21/28) compared to 39% (11/28) for ⁶⁸Ga-PSMA-11.

These results further build on the growing body of evidence showing that ⁶⁴Cu-SAR-bisPSMA improves the detection of prostate cancer, compared to the current SOC prostate-specific membrane antigen (PSMA) PET agents which are known to have low sensitivity, with limited ability to detect cancer, especially in patients with low PSA levels^[3],[4],[5].

Further data outlining results from the Co-PSMA IIT will be announced in mid-March following their oral presentation at the EAU 2026.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “The data from the Co-PSMA trial are nothing short of exceptional. We already knew of the significant benefits of the optimised bisPSMA molecule from the early days around 7 years ago, when it was purposely developed to overcome the many shortfalls of the current single-targeting SOC PSMA imaging agents. This innovative benchtop research of the dual-targeting bisPSMA agent quickly progressed to multiple clinical trials, including COBRA^[6], PROPELLER^[7] and SECuRE^[8], which enabled us to secure three Fast Track Designations from the United States (US) Food and Drug Administration (FDA) and advance to two registrational trials, AMPLIFY^[9] and CLARIFY^[10], both of which are nearing completion of recruitment.

“Importantly, in the COBRA trial, we also looked at the performance of ⁶⁴Cu-SAR-bisPSMA in patients with BCR of prostate cancer following definitive therapy, but with participant selection criteria having no limitation on upper PSA levels (median 0.9 ng/mL, range 0.25 to 17.6). The Co-PSMA data we are seeing to date reinforces the COBRA trial findings where more lesions and patients with a positive scan were identified using ⁶⁴Cu-SAR-bisPSMA compared to SOC PSMA PET products, including ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL^[6]. A subset of participants in the COBRA trial had a follow-up SOC PSMA PET. While 90% of these participants had a positive scan on the initial ⁶⁴Cu-SAR-bisPSMA next-day imaging, only 60% were positive on SOC PSMA PET, despite median scan time from the first ⁶⁴Cu-SAR-bisPSMA imaging to the follow-up scan being 73.5 days. The number of lesions across all participants (average sum of lesions across all readers) identified by ⁶⁴Cu-SAR-bisPSMA on next-day imaging was >2.6 times higher than that detected by SOC PET agents (52.6 vs 20 lesions)^[6].

“What we are learning today from the head-to-head Co-PSMA study is a valuable insight into how ⁶⁴Cu-SAR-bisPSMA directly compares against ⁶⁸Ga-PSMA-11, further bolstering the data seen to date. Similar to COBRA, Co-PSMA demonstrated that our product was able to identify more than 2.5 times total number of lesions on the next-day imaging in comparison to the SOC. Furthermore, 4 out of every 5 participants had a positive scan for prostate cancer using ⁶⁴Cu-SAR-bisPSMA, compared to only 2 in 5 participants using ⁶⁸Ga-PSMA-11, therefore making ⁶⁴Cu-SAR-bisPSMA far more reliable than ⁶⁸Ga-PSMA-11 in detecting the presence of cancer in these patients. These findings, coupled with the much higher true positive rate of ⁶⁴Cu-SAR-bisPSMA (75% vs. 39% for ⁶⁸Ga-PSMA-11), will enable clinicians to treat prostate cancer more effectively and with a greater level of confidence based on the accurate detection of disease. These results speak for themselves, clearly illustrating that ⁶⁴Cu-SAR-bisPSMA considerably outperforms its competitors in detecting prostate cancer recurrence. Moreover, this sheds light on the importance of the improved lesion detection, where the diagnostic benefits translate into enhanced patient management: almost half of the Co-PSMA and COBRA study participants had a change of their planned disease management as a result of the ⁶⁴Cu-SAR-bisPSMA findings^[6], which could be absolutely game-changing for clinicians and their patients. This is the difference between allowing prostate cancer lesions to grow or having a clear diagnosis and an active and highly targeted treatment plan. Earlier intervention in BCR can prevent cancer growth and spread, avoid side effects from systemic therapies and considerably improve patient outcomes.

“The current market for PSMA PET imaging in the US alone is around US$2 billion per year, and this is expected to further grow to over US$3 billion by 2029. Unfortunately, this blockbuster market is dominated by ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL, both of which have low sensitivity^[4],[5]. The development pipeline of new products, excluding ⁶⁴Cu-SAR-bisPSMA, offers no significant differentiation from the existing agents, with some new entrants commercialising the unpatented ⁶⁸Ga-PSMA-11 agent, which has been capitalised on by three separate groups already. Time and time again we are seeing significant clinical and logistical benefits offered by ⁶⁴Cu-SAR-bisPSMA through our trials. We strongly believe this product could not only become the new SOC in PSMA PET but also grow the market opportunity further by substantially improving the diagnosis of prostate cancer in many stages of the disease, from its early phases pre-definitive therapy, through to better identification of lesions in the BCR setting, including in patients with oligometastatic disease.

“While the AMPLIFY and CLARIFY trials are key to getting ⁶⁴Cu-SAR-bisPSMA towards commercialisation, Co-PSMA provides further evidence of its benefits to clinicians and prostate cancer patients. This makes the paradigm shift towards improved diagnostics a no-brainer due to our relentless focus on rigorous clinical development and commitment to strong science to change the lives of people living with cancer. The acceptance of the Co-PSMA data by a world-leading urology conference as an oral presentation is a testament to the strength and quality of the data, generated by Prof Emmett, a global key opinion leader in the field.”

Prof Louise Emmett (St Vincent’s Hospital Sydney), Principal Investigator in the Co-PSMA trial, commented, “While approved PSMA PET agents are highly specific, their low sensitivity at low PSA levels means that many patients with early rising PSA show no detectable disease, making treatment planning challenging. More sensitive diagnostics that remain highly specific are needed for effective early intervention in BCR. Our research demonstrates that ⁶⁴Cu-SAR-bisPSMA PET/CT offers a significant advancement in the detection of recurrent prostate cancer. Compared to ⁶⁸Ga-PSMA-11, the 24-hour ⁶⁴Cu-SAR-bisPSMA images identified the site of disease recurrence in a higher proportion of patients, directly informing tailored treatment decisions for men in BCR. These findings highlight the potential for ⁶⁴Cu-SAR-bisPSMA to improve patient outcomes.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

Disclaimer

⁶⁴Cu-SAR-bisPSMA is an unregistered product. The safety and efficacy of ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[11]. Prostate cancer is the second-leading cause of cancer death in American men. The American Cancer Institute estimates there will be about 333,830 new cases of prostate cancer in the US in 2026 and around 36,320 deaths from the disease^[12].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

References

This announcement has been authorised for release by the Executive Chairperson.

SHIJIAZHUANG, China, Feb 16, 2026 /PRNewswire/ — The Hebei Daily International Communication Center has released a new micro-documentary titled ‘Side by Side: Across Oceans and Mountains, Joining China to Greet the Dawn’ (the “Documentary”), highlighting the stories of international individuals who supported China during World War II.

Hebei Daily International Communication Center Launches Historical Micro-Documentary ‘Side by Side’

The release comes as 2025 marks the 80th anniversary of the end of World War II and the victory over fascism. The Documentary revisits a lesser-known chapter of wartime history: how foreign doctors, volunteers, and supporters worked alongside Chinese communities during the conflict, particularly in the Taihang Mountains region.

The Documentary features Michael Crook, Chairman of the International Committee for the Promotion of Chinese Industrial Cooperatives and son of David and Isabel Crook, who shares personal accounts of international figures who played a role in China during the war. These include Dr. Norman Bethune, Dwarkanath Kotnis, Kathleen Hall, and Richard Frey.

Through interviews and historical storytelling, the Documentary reflects on how cross-border cooperation and humanitarian support shaped lives during one of the darkest periods of the 20th century. It also invites audiences to revisit the human dimension of wartime history and the enduring impact of international solidarity.

Backed by the Finvasia Group, Dealing offers investors access to 30,000+ financial assets across 120+ countries and 10+ global exchanges through a single account

DUBAI, UAE, Feb. 16, 2026 /PRNewswire/ — Dealing , a new global investing platform, has launched with a mission to transform how investors access and participate in global financial markets. Built as an investment-first platform, Dealing is designed for long-term investors focused on diversification, discipline, and sustainable wealth creation.

Dealing Team at the launch event

Dealing enables investment in 30,000+ financial assets across 10+ global markets from countries such as the United States, United Kingdom, Hong Kong, Singapore, Germany, Canada and Australia operating under 30+ licenses and registrations- all through a single unified account across stocks, ETFs, derivatives, and other global instruments.

The global investing platform is first consumer-facing offering from Mauritius-headquartered Dealing Investment Banking Services, which provides corporate finance advisory, product structuring and distribution, wealth and investment advisory, market making, brokerage and execution services through the global investing platform.

Tajinder Virk, Co-Founder and CEO, Finvasia Group and Dealing said, “Dealing was born from a simple insight: global investing isn’t a lack of opportunity, it’s the complexity and fragmentation that hold most investors back. Even today, around 90% of global stocks remain out of reach for individual investors. Dealing removes these barriers, uniting global markets, opportunities, and assets into a single, transparent experience so investors can participate confidently and focus on long-term wealth creation. Part of Dealing Investment Banking Services, the platform aims to revolutionize investment banking – our first step in bringing it to the masses.”

Backed by the Finvasia Group, Dealing Investment Banking Services operates within a robust global regulatory framework, including an FSC Mauritius Investment Banking License, CySEC regulation, and the UAE Securities and Commodities Authority (SCA), alongside other international registrations, serving investors across 120+ countries.

Dealing launched at IFX Dubai Expo, a leading global fintech and trading forum, and will first expand across the GCC, then into Europe, Africa — including South Africa — and other key markets.

About Dealing Global Investing Platform: 

Dealing is a global investing platform designed to make multi-market investing simple, transparent, and accessible through a seamless mobile and web experience. Backed by the Finvasia Group, Dealing offers access to global stocks, ETFs, derivatives, and alternative instruments through a single account, supported by direct regulatory licensing and a fully owned technology stack. For more information, visit: https://dealing.com/en-NL.